Cero Therapeutics Holdings, Inc. financial data

Symbol
CERO, CEROW on Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
Location
201 Haskins Way, Suite 230, South San Francisco, CA
State of incorporation
DE
Fiscal year end
December 31
Former names
PHOENIX BIOTECH ACQUISITION CORP. (to 2/14/2024)
Latest financial report
10-K - Q4 2024 - Apr 15, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 46.1 %
Debt-to-equity -342 % -512%
Return On Equity 257 % +3108%
Return On Assets -106 % -594%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 5.38M shares -63.5%
Common Stock, Shares, Outstanding 5.85K shares
Entity Public Float 5.77M USD +114%
Common Stock, Value, Issued 1 USD -98.9%
Weighted Average Number of Shares Outstanding, Basic 579K shares
Weighted Average Number of Shares Outstanding, Diluted 579K shares

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 6.32M USD +20.8%
General and Administrative Expense 8.99M USD +782%
Operating Income (Loss) -15.3M USD -134%
Nonoperating Income (Expense) 7.57M USD +752%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -308K USD -313%
Income Tax Expense (Benefit) 25.8K USD -57.4%
Net Income (Loss) Attributable to Parent -7.73M USD
Earnings Per Share, Basic -18.2 USD/shares +81.8%
Earnings Per Share, Diluted -18.2 USD/shares +81.8%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 96.9K USD -79.6%
Assets, Current 3.71M USD +88.5%
Property, Plant and Equipment, Net 529K USD -45.3%
Operating Lease, Right-of-Use Asset 1.46M USD -33.1%
Assets 6.21M USD +21.1%
Accounts Payable, Current 4.51M USD +170%
Employee-related Liabilities, Current 244K USD +256%
Accrued Liabilities, Current 1.91M USD +1223%
Liabilities, Current 7.4M USD +111%
Operating Lease, Liability, Noncurrent 699K USD -55.6%
Liabilities 8.1M USD +59.4%
Retained Earnings (Accumulated Deficit) -70.9M USD -64.6%
Stockholders' Equity Attributable to Parent -1.89M USD +95.5%
Liabilities and Equity 6.21M USD +21.1%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -198K USD +35.8%
Net Cash Provided by (Used in) Investing Activities -100K USD
Common Stock, Shares Authorized 45.4M shares
Common Stock, Shares, Issued 5.85K shares
Common Stock, Par or Stated Value Per Share 0 USD/shares
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -298K USD +3.35%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 3.33M USD +108%
Deferred Tax Assets, Valuation Allowance 17.6M USD +29.7%
Deferred Tax Assets, Gross 17.6M USD +29.7%
Operating Lease, Liability 1.58M USD -32.8%
Depreciation 114K USD -1.33%
Lessee, Operating Lease, Liability, to be Paid 1.72M USD
Operating Lease, Liability, Current 876K USD +14%
Lessee, Operating Lease, Liability, to be Paid, Year Two 726K USD
Lessee, Operating Lease, Liability, to be Paid, Year One 990K USD
Operating Lease, Weighted Average Discount Rate, Percent 0.1 pure
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 141K USD
Deferred Tax Assets, Operating Loss Carryforwards 12.2M USD +34.9%
Preferred Stock, Shares Issued 4M shares
Deferred Federal Income Tax Expense (Benefit) 182K USD
Preferred Stock, Shares Authorized 1M shares 0%
Unrecognized Tax Benefits 538K USD +17.2%
Additional Paid in Capital 1.03M USD
Preferred Stock, Shares Outstanding 0 shares
Share-based Payment Arrangement, Expense 925K USD
Interest Expense 14.4K USD
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%